Replies to post #1225 on InMed Pharmaceuticals Inc (INM)

[lesgetrich]

According to their investor presentation, they are scheduled to report on Phase 1/2a Clinical trials on INM-750 their EB drug in Q4, 2016 and initiate Phase 1 of their glaucoma drug INM-085 in the same quarter. Perhaps the market is anticipating some news on that.